HYDERABAD, INDIA (Jan 11, 2017) – SuvenInc a wholly owned subsidiary of Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of the unmet medical needs in neurodegenerative disorders today announced that it is participating in the 35th J.P. Morgan Healthcare Conference being held in San Francisco, USA during 9th to 12th Jan 2017 and presenting at Biotech Showcase 2017on 11th Jan 2017 at9.30 am PT.
J.P. Morgan Healthcare conference is the premier conference of its kind, bringing together established industry leaders, emerging fast-growth companies, innovative technology creators and globally minded service providers who will deliver presentations to more than 4,000 investors. This conference puts you at the center of the investment and partnering community and provides an open format to connect with the funding partners.
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.
Mr. Venkat Jasti is scheduled to discuss the company’s corporate overview, business strategy and clinical development pipeline at Biotech Showcase 2017 where the world’s top notch investment professionals will present along with the most innovative companies who are decision makers. Mr. Venkat Jasti and other members of the management team will be available for one-on-one meetings at the conference.
SuvenInc’s near-term focus is to develop the product candidate SUVN-502, for the treatment of Alzheimer's disease and other forms of dementia with the ongoing phase 2a multicenter, randomized, double-blind, parallel group, 26-week, placebo-controlled study of SUVN-502 in subjects with moderate Alzheimer’s disease currently treated with Donepezil Hydrochloride and Memantine Hydrochloride.
